News & Events
ProteoDesign secures a 1.7M€ financing round led by Caixa Capital Risc
ProteoDesign, a biotech spin-out from Princeton University developing personalized immunotherapies in cancer, announced the successful closing of a 1.7M€ financing round.
read moreProteoDesign to attend BIO-Europe Spring 2018 in Amsterdam
ProteoDesign will be attending BIO-Europe Spring 2018 in Amsterdam.
read moreProteoDesign’s fight against cancer featured in “ARA” newspaper
Our CEO Miquel Vila-Perelló shared his views on the personalized approach ProteoDesign is developing to fight cancer, along with other entrepreneurs in the field....
read moreMiquel Vila-Perelló interviewed by the CataloniaBio newsletter
Miquel Vila-Perelló was interviewed by the Bionews online newsletter from CataloniaBio. Link
read moreProteoDesign leads the ToxAb consortium awarded with a “RETOS de Colaboración” grant
The project “ToxAb”, which is devoted to the development of novel Antibody-Drug Conjugates (ADCs), has won a “RETOS-Colaboración” grant from the Ministry of Economy and Competitiveness of Spain (RTC-2014-1685-1). ProteoDesign leads the consortium which includes the...
read moreProteoDesign attends 2015 BIO International Convention
ProteoDesign attended the BIO2015 meeting in Philadelphia, the annual gathering of the global biotech industry. ProteoDesign, represented by Miquel Vila-Perelló, attended as part of the Catalan delegation coordinated by BioCat. Miquel also participated in the NJ...
read more“La Caixa” invests in ProteoDesign
ProteoDesign has closed a round of financing lead by Caixa Capital Risc. These funds will allow ProteoDesign to complete the first phase of its ADC development program. ”la Caixa” participates in this operation through the Caixa Innvierte BioMed II fund.
read moreProteoDesign participates in the Falling Walls 2014 meeting in Berlin
ProteoDesign presented its Streamlined Expressed Protein Ligation technology at the Falling Walls 2014 Venture meeting. The Falling Walls Venture forum is held during the annual celebration of the Falling Walls meeting in Berlin, and gathers outsanding science based...
read moreProteoDesign participates in the INPACT Consortium
ProteoDesign is a member of the INPACT Consortium, which has recently been awarded a Research and Innovation Staff Exchange (RISE) grant by the European Commission. The INPACT (Innovative Peptides Against Cancer and Pathogenic Bacteria) project aims to develop a...
read moreCaixa Capital Risc invests in ProteoDesign through its seed investment vehicle
ProteoDesign signed a particpative loan with Caixa Capital Micro SCR.
read more